Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
This study aimed to investigate the association of gastrointestinal (GI) adverse events of cinacalcet with gallstones in the hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). A total of 23 HD patients under the treatment with cinacalcet and 101 control patients were enrolled in t...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-10-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/0886022X.2017.1419971 |
| _version_ | 1798043296005619712 |
|---|---|
| author | Keiichi Otsuka Yoichi Ohno Joji Oshima |
| author_facet | Keiichi Otsuka Yoichi Ohno Joji Oshima |
| author_sort | Keiichi Otsuka |
| collection | DOAJ |
| description | This study aimed to investigate the association of gastrointestinal (GI) adverse events of cinacalcet with gallstones in the hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). A total of 23 HD patients under the treatment with cinacalcet and 101 control patients were enrolled in this cross-sectional study. We investigated the prevalence of gallstones and the association of GI adverse events of cinacalcet with gallstones. The prevalence of gallstones was significantly higher in the HD patients with cinacalcet compared with the controls (47.8% vs. 15.8%). The longer time on HD, hypercalcemia, hyperphosphatemia and elevated parathyroid hormone level were observed in the HD patients with cinacalcet. Besides, GI adverse events of cinacalcet were observed more frequently in the HD patients with gallstones compared with those without gallstones (odds ratio 13.5, 95% CI: 1.80–101). Therefore, screening for gallstones before dosing cinacalcet may reduce the risk of GI adverse events in SHPT patients. |
| first_indexed | 2024-04-11T22:47:19Z |
| format | Article |
| id | doaj.art-8c7acf67ae034c23b64b55b35bb9aeb1 |
| institution | Directory Open Access Journal |
| issn | 0886-022X 1525-6049 |
| language | English |
| last_indexed | 2024-04-11T22:47:19Z |
| publishDate | 2018-10-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj.art-8c7acf67ae034c23b64b55b35bb9aeb12022-12-22T03:58:43ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492018-10-01401384210.1080/0886022X.2017.14199711419971Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidismKeiichi Otsuka0Yoichi Ohno1Joji Oshima2Department of Internal Medicine, Oshima ClinicSaitama Medical SchoolDepartment of Internal Medicine, Oshima ClinicThis study aimed to investigate the association of gastrointestinal (GI) adverse events of cinacalcet with gallstones in the hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). A total of 23 HD patients under the treatment with cinacalcet and 101 control patients were enrolled in this cross-sectional study. We investigated the prevalence of gallstones and the association of GI adverse events of cinacalcet with gallstones. The prevalence of gallstones was significantly higher in the HD patients with cinacalcet compared with the controls (47.8% vs. 15.8%). The longer time on HD, hypercalcemia, hyperphosphatemia and elevated parathyroid hormone level were observed in the HD patients with cinacalcet. Besides, GI adverse events of cinacalcet were observed more frequently in the HD patients with gallstones compared with those without gallstones (odds ratio 13.5, 95% CI: 1.80–101). Therefore, screening for gallstones before dosing cinacalcet may reduce the risk of GI adverse events in SHPT patients.http://dx.doi.org/10.1080/0886022X.2017.1419971Cinacalcet hydrochloridegallstonesgastrointestinal adverse eventshemodialysissecondary hyperparathyroidism |
| spellingShingle | Keiichi Otsuka Yoichi Ohno Joji Oshima Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism Renal Failure Cinacalcet hydrochloride gallstones gastrointestinal adverse events hemodialysis secondary hyperparathyroidism |
| title | Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism |
| title_full | Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism |
| title_fullStr | Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism |
| title_full_unstemmed | Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism |
| title_short | Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism |
| title_sort | gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism |
| topic | Cinacalcet hydrochloride gallstones gastrointestinal adverse events hemodialysis secondary hyperparathyroidism |
| url | http://dx.doi.org/10.1080/0886022X.2017.1419971 |
| work_keys_str_mv | AT keiichiotsuka gallstoneswereassociatedwiththegastrointestinaladverseeventsofcinacalcetinhemodialysispatientswithsecondaryhyperparathyroidism AT yoichiohno gallstoneswereassociatedwiththegastrointestinaladverseeventsofcinacalcetinhemodialysispatientswithsecondaryhyperparathyroidism AT jojioshima gallstoneswereassociatedwiththegastrointestinaladverseeventsofcinacalcetinhemodialysispatientswithsecondaryhyperparathyroidism |